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Abstract
Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have
commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist ‘Smac mimetic’ compounds
for the treatment of cancer. These trials represent the culmination of a line of research that
commenced with analysis of how insect viruses stop host cells from killing themselves and led to the
discovery of a family of proteins that regulate development in insects and signalling by tumour necrosis
factor superfamily members in mammals, which prompted development of drugs that mimic natural
IAP-binding proteins to promote cell death.
Introduction and context
Inhibitor of apoptosis (IAP) proteins were identified by
Lois Miller and colleagues [1] in a screen for baculoviral
genes that could prevent apoptosis of insect cells infected
with a virus in which the caspase-inhibitory gene p35 was
mutated. Analysis of the sequence of this IAP showed
that it bore two domains, termed baculoviral IAP repeats
(BIRs), and a carboxy-terminal RING domain. In
mammals, four proteins that have one or more BIR
domains and a carboxy-terminal RING domain have
been identified, namely cellular IAP 1 (cIAP1)/BIRC2,
cIAP2/BIRC3, X-linked IAP protein (XIAP)/BIRC4, and
melanoma IAP protein (ML-IAP)/BIRC7 [2] (Figure 1).
Increased expression of these IAPs has been observed in
many types of cancer. For example, the locus encom-
passing cIAP1 and cIAP2 is amplified in hepatocellular
carcinomas, high levels of XIAP have been reported in
cervical cancers, and ML-IAP levels are high in mela-
noma. In addition, cIAP2 is involved in translocations
seen in MALT (mucosa-associated lymphoid tissue)
lymphomas. Associations such as these suggest that
IAPs might be oncogenic, and if so, targeting them
pharmaceutically might be therapeutic [3].
Clues to the identification of natural IAP antagonists
came from studying IAPs in Drosophila, which has two
BIR-containing proteins with carboxy-terminal RING
domains: Drosophila IAP protein 1 (DIAP1) and DIAP2
[4]. Deletion of DIAP1 leads to massive inappropriate
cell death during development, resulting in embryonal
lethality. Mutations in DIAP1 also enhanced cell death
caused by overexpression of the small pro-apoptotic
protein Reaper [5]. Subsequently, it was shown that
Reaper and proteins encoded by three closely linked
genes, grim, hid, and sickle, bound directly to the second
BIR of DIAP1 and blocked its anti-apoptotic function [6].
Mammalian IAP-binding proteins were identified by
mass spectrometric analysis of proteins co-immuno-
precipitating with IAPs from cell lysates [7,8]. These
mitochondrial proteins, including Smac/Diablo and
HtrA2/Omi, bore processed amino-termini similar to
the amino-termini of Reaper, Grim, HID, and Sickle [9].
Crystallisation of a Smac-BIR3 of XIAP complex [10]
showed that the key interaction was between the four
conserved amino-terminal amino acids of the IAP-
binding protein with a hydrophobic pocket on the
surface of the BIR.
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resemble the amino-termini of the IAP-binding proteins
have been designed to allow pharmacological antagon-
ism of IAPs. Experiments using these compounds have
revealed that they cause apoptosis by modifying tumour
necrosis factor (TNF) signalling pathways [11-14].
Despite its name, TNF is only very rarely able to cause cell
death on its own and must be combined with inhibitors
of transcription or translation, such as actinomycin D or
cycloheximide. This implied activity of certain ‘survival’
genes prevented death of cells treated with TNF alone.
Observations that cells lacking the nuclear factor-kappa-
B( N F - kB) component p65/RelA were susceptible to TNF
alone suggested that the survival genes were driven by
NF-kB [15].
Major recent advances
The first connection between IAPs and TNF signalling
pathways came with the identification of cIAP1 and
cIAP2 in a complex with TNF receptor-associated factor 1
(TRAF1) and TRAF2 that bound to the cytoplasmic
domain of TNF receptor 2 (TNFR2) [16]. Subsequently, it
was shown that BIR1 of cIAP1 allows it to bind to the
TRAFs [17,18].
More recently, it was found that mouse embryonic
fibroblasts (MEFs) mutant for cIAP1 could be killed by
TNF alone, just like p65/RelA mutant MEFs [12]. This,
studied in cells depleted of cIAP1, cIAP2, or both [19,20],
revealed that cIAPs are needed for TNF to activate p65/
RelA NF-kB.
Remarkably, addition of an IAC to cells causes cIAP1 to
be ubiquitylated and degraded in under half an hour
[11-14] (Figure 2). In some cells, XIAP also disappears,
but it usually takes longer and might sometimes be due
to cleavage by caspases rather than by the proteasome. By
depleting cells of cIAP1 and cIAP2, IACs have cast a new
light on what these IAPs actually do.
TNF alone can kill cIAP1 mutant MEFs and MEFs
pretreated with IACs but does not kill XIAP mutant
MEFs [12]. This suggests that, in the TNF-triggered death
pathway, the targets of IACs are the cIAPs rather than
XIAP, and because XIAP is the only IAP that directly
inhibits caspase activity [21], it means that IACs do not
kill purely by relieving caspase inhibition. Even so,
antagonism of XIAP might be important for blocking
other death pathways as cIAP-selective antagonists are
less potent in promoting apoptosis than pan-selective
compounds [22], and sensitisation to other death
receptor ligands might require inhibition of XIAP in
certain types of cells [23].
Cell lines that are killed by IACs produce autocrine TNF,
and blocking TNF receptors prevents the cells from
dying. But IACs also sensitise cells to the addition of
death receptor ligands such as TNF, Fas ligand, or TNF-
related apoptosis-inducing ligand (TRAIL). This implies
that one of the normal functions of cIAPs is to prevent or
reduce activation of caspase 8 in response to death
ligands (Figure 3).
MEFs treated with IACs, or those in which genes for
cIAP1 or TRAF2 are deleted, have constitutively elevated
levels of NF-kB-inducing kinase (NIK) [11,12], and
activation of the downstream non-canonical NF-kB
pathway, evidenced by low levels of NF-kB2/p100
relative to its product NF-kB2/p52 (Figure 4). Activation
of this transcription factor pathway might explain the
autocrine production of TNF in some cell types. The
Figure 1. Cellular inhibitor of apoptosis 1 (cIAP1) and cIAP2 have
three baculoviral inhibitor of apoptosis repeat (BIR) domains
BIR1 binds to tumour necrosis factor receptor-associated factor 1 (TRAF1)
and TRAF2; BIR2 and BIR3 bind to Smac/Diablo and IAP antagonist
compounds (IACs). The BIRs are followed by a ubiquitin-associated (UBA)
domain that allows binding to ubiquitin [33]. This is followed by a caspase
recruitment domain (CARD), but no proteins that bind to the CARD of
IAPs have been identified. At the carboxy-terminus is a RING domain that
allows dimerisation and confers ubiquitin E3 ligase activity.
Figure 2. Inhibitor of apoptosis antagonist compounds (IACs)
trigger dimerization-dependent autoubiquitylation and
degradation of inhibitors of apoptosis (IAPs)
When an IAC ‘Smac-mimetic’ (green triangles) is added to cells, it binds to
baculoviral inhibitor of apoptosis repeat 2 (BIR2) and BIR3 of cellular IAP 1
(cIAP1). This somehow allows RING dimerisation of cIAP1, which becomes
ubiquitylated (black dots) and degraded by the proteasome. Tumour
necrosis factor receptor-associated factor 2 (TRAF2) levels are unaffected
by addition of IACs.
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k and experiments in which TNF activation of NF- B wasactivation of NIK when cIAPs are depleted suggests that a
normal role for cIAPs and TRAFs is to channel NF-kB
signalling toward the p65/RelA pathway and away from
the NIK-activated pathway. For example, when cIAP1 is
genetically deleted, phosphorylation and activation of
p65/RelA in response to TNF are greatly reduced and
delayed, whereas NIK levels are elevated, even in the
absence of cytokine stimulation (Figure 4).
So how is TNF able to activate E3 activity of cIAP1 and
cIAP2? Like XIAP, cIAP1 and cIAP2 bear carboxy-
terminal RING domains, which allow them to act as
ubiquitin ligases [24]. IAPs can hetero- and homo-
dimerise via their RINGs, which seems to activate them,
allowing them to associate with an E2 and leading to
their auto-ubiquitylation and degradation by the protea-
some [25] (Figure 2). Although it is clear that binding
of an IAC to the BIR of an IAP results in activation of
its RING, exactly how they do so it not known as the
three-dimensional structure of a whole IAP has not yet
been determined.
Mutation of residues at the very end of a cIAP1’sR I N G
greatly increases its half-life, but these mutants lose anti-
apoptotic activity. This suggests that cIAP1 must dimerise
at their RINGs in order to activate, and then they
ubiquitylate themselves and other associated proteins,
such as receptor-interacting serine/threonine kinase 1
(RIPK1) [19,20,26,27], caspases [28], or Smac/Diablo
[18]. Itispossible that, whencells are exposed toIACs, the
IAPs autoubiquitylate and destroy themselves, so they are
no longer able to ubiquitylate their physiological targets.
This prevents p65/RelA from being activated, while NIK is
stabilised, causing processing and activation of p100/NF-
kB2 signalling and autocrine production of TNF.
WhenIACswere giventomice bearing xenografttumours,
the malignant cells were killed, apparently without
stimulation of a TNF cytokine storm causing severe side
effects [11,13]. This was encouragement enough to
commence phase I trials in humans, but as yet, no results
from Genentech, Inc. (South San Francisco, CA, USA),
Figure 3. Signalling in response to tumour necrosis factor (TNF)
is regulated by inhibitors of apoptosis (IAPs)
When TNF binds to TNF receptor 1 (TNFR1), it stimulates formation of a
complex containing TRADD (TNFR superfamily 1A-associated via death
domain), RIPK1 (receptor-interacting serine-threonine kinase 1), TRAF2
(TNFR-associated factor 2), cIAP1 (cellular IAP 1), and other proteins.
RIPK1 becomes K63 ubiquitylated, inhibitor of kappa-B is phosphorylated
and degraded, and the canonical nuclear factor-kappa-B (NF-kB) component
p65/RelA is released and enters the nucleus. If cIAP1 is removed (by gene
deletion or addition of an inhibitor of apoptosis antagonist compound),
TNF triggers formation of a second complex containing TRADD, FADD
(Fas-associated protein with death domain), RIPK1, and caspase 8, which
become activated, leading to apoptosis. TAK1, transforming growth factor
(TGF)-beta activated kinase 1.
Figure 4. In the absence of tumour necrosis factor (TNF), cellular
inhibitor of apoptosis 1 (cIAP1) constitutively suppresses nuclear
factor-kappa-B (NF-kB)-inducing kinase (NIK) abundance
In cells that have not been exposed to cytokines, a complex containing
cIAP1, TNF receptor-associated factor 2 (TRAF2), and TRAF3 interacts
with NIK, causing it to be ubiquitilated and degraded, so that steady-state
levels of NIK are very low. When cIAP1 is depleted by addition of an IAP
antagonist compound or when genes for cIAP1 or TRAF2 are deleted, NIK
levels rise, leading to cleavage and activation of the non-canonical NF-kB
member p100/NF-kB2 by generation of the active product, p52. TNFR1,
TNF receptor 1.
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Genome Sciences (Rockville, MD, USA), or Novartis
(Basel, Switzerland) have been reported.
Future directions
Many puzzles remain to be solved in the lab: How does
binding of an IAC to the BIR lead to activation of the E3
ligase? What are the direct substrates of IAP E3 activity
[RIPK1, RIPK2, Smac/Diablo, ASK1 (apoptosis signal-
regulating kinase 1), and caspases are among the reported
substrates] [26,29-32]? Are these proteins modified by
K48, K63, or linear linked ubiquitin? When cIAPs are
doing their ‘day job’ of reducing NIK levels, do they have
to be activated by a BIR-binding protein, and if so, what is
it? What is the effect of deletion of both cIAP1 and cIAP2?
What are the differences between cIAP1 and cIAP2, and
what is the role of the caspase recruitment domains and
ubiquitin-associated domains in these proteins? We will
have to wait and see, just as we will for the clinical trials,
which will reveal whether IACs will be therapeutically
useful, either as a single agent or in combination with
TRAIL or conventional chemotherapy.
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